title: [Early detection of anthracyclines cardiotoxicity by tissue Doppler echocardiography about 45 cases at Abidjan institute of cardiology].
abstract: OBJECTIVE
  Evaluate the early anthracyclines cardiotoxicity.
  
  
  METHODS
  It is a prospective study made on 10 months of period from October 2008 to July 2009 and on patients who contracted a solid canny tumor hospitalized or followed in their movement and who would receive chemotherapy with an anthracycline molecule. On this effect, we have used tissue Doppler of mitral ring to detect clinic infratoxicity.
  
  
  RESULTS
  Forty-five patients (43 women and 2 men) who contracted the solid cancers were included in the study. The patients were 48 of age in average ± 10.12. All our patients did not show any cardiovascular symptoms at the time of the study. Cardiothoracic and electrocardiograms were not significantly modified by the chemotherapy. The cardioecography with the use of tissue Doppler revealed as followed: (a) significant low of the ejection fraction and the pick of systolic myocardia wave (Sa) on four patients (8.8%). These concerned patients were considered as having anthracycline cardio toxicity. The factor causing this cardiotoxicity was the nature of the anthracycline, which was used: the doxorubicin. The quantity accumulated threshold of the doxorubicin that shod (where toxicity appeared was 150 mg/m(2)); (b) a low of Sa pick without that of left ventricular fraction ejection observed on five patients (11.11%). These concerned patients were considered as having potential risks to develop anthracyclines cardiotoxicity; (c) the left ventricular ejection fraction was not a good indicator the check up of the patients under chemotherapy made up with anthracyclines.
  
  
  CONCLUSIONS
  The tissue Doppler not only enables to make diagnostics of early myocardia dysfunctions but it mainly allows to identify people with risks of a cardiotoxicity due to a going on chemotherapy.
authors.affiliation: Service de cardiologie, CHU Tokoin de Lomé, Machihude PIO, BP 14148, Lomé, Togo. pimae2002@yahoo.fr
authors.forename: M
authors.initials: M
authors.lastname: Pio
authors.forename: K
authors.initials: K
authors.lastname: Adoubi
authors.forename: A
authors.initials: A
authors.lastname: Adoh
authors.forename: C
authors.initials: C
authors.lastname: Didi-Kouko
authors.forename: J-B
authors.initials: JB
authors.lastname: Anzouan-Kacou
authors.forename: A
authors.initials: A
authors.lastname: Tegnan
authors.forename: I
authors.initials: I
authors.lastname: Adoubi
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D054715:Cardiotoxins / Q000627:therapeutic use / Q000633:toxicity*; D003906:Developing Countries; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use / Q000633:toxicity; D015150:Echocardiography, Doppler / Q000379:methods*; D015251:Epirubicin / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000000981:diagnostic imaging / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D013318:Stroke Volume / Q000187:drug effects; D013599:Systole / Q000187:drug effects; D014037:Togo; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced / Q000000981:diagnostic imaging
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D015251:Epirubicin; D004317:Doxorubicin